These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 31392115)

  • 21. The effect of nitisinone on homogentisic acid and tyrosine: a two-year survey of patients attending the National Alkaptonuria Centre, Liverpool.
    Milan AM; Hughes AT; Davison AS; Devine J; Usher J; Curtis S; Khedr M; Gallagher JA; Ranganath LR
    Ann Clin Biochem; 2017 May; 54(3):323-330. PubMed ID: 28081634
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of low dose nitisinone in the management of alkaptonuria.
    Sloboda N; Wiedemann A; Merten M; Alqahtani A; Jeannesson E; Blum A; Henn-Ménétré S; Guéant JL; Renard E; Feillet F
    Mol Genet Metab; 2019 Jul; 127(3):184-190. PubMed ID: 31235217
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessment of the Effect of Once Daily Nitisinone Therapy on 24-h Urinary Metadrenalines and 5-Hydroxyindole Acetic Acid Excretion in Patients with Alkaptonuria After 4 Weeks of Treatment.
    Davison AS; Norman B; Milan AM; Hughes AT; Khedr M; Rovensky J; Gallagher JA; Ranganath LR
    JIMD Rep; 2018; 41():1-10. PubMed ID: 29147990
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ochronotic osteoarthropathy in a mouse model of alkaptonuria, and its inhibition by nitisinone.
    Preston AJ; Keenan CM; Sutherland H; Wilson PJ; Wlodarski B; Taylor AM; Williams DP; Ranganath LR; Gallagher JA; Jarvis JC
    Ann Rheum Dis; 2014 Jan; 73(1):284-9. PubMed ID: 23511227
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adequacy of nitisinone for the management of alkaptonuria.
    Abbas K; Basit J; Rehman MEU
    Ann Med Surg (Lond); 2022 Aug; 80():104340. PubMed ID: 36045846
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Asymptomatic Corneal Keratopathy Secondary to Hypertyrosinaemia Following Low Dose Nitisinone and a Literature Review of Tyrosine Keratopathy in Alkaptonuria.
    Khedr M; Judd S; Briggs MC; Hughes AT; Milan AM; Stewart RMK; Lock EA; Gallagher JA; Ranganath LR
    JIMD Rep; 2018; 40():31-37. PubMed ID: 28942493
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluating the aortic stenosis phenotype before and after the effect of homogentisic acid lowering therapy: Analysis of a large cohort of eighty-one alkaptonuria patients.
    Ranganath LR; Heseltine T; Khedr M; Fisher MF
    Mol Genet Metab; 2021 Jul; 133(3):324-331. PubMed ID: 34059444
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Joint replacement risk is markedly increased in alkaptonuria (AKU) in those with prior arthroplasty.
    Ranganath LR; Khedr M; Norman BP; Hughes JH; Imrich R; Arnoux JB; Olsson B; Rudebeck M; Gallagher JA; Bou-Gharios G
    Mol Genet Metab Rep; 2024 Sep; 40():101097. PubMed ID: 38846518
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of changes in the tyrosine pathway by 24-h profiling during nitisinone treatment in alkaptonuria.
    Ranganath LR; Milan AM; Hughes AT; Davison AS; Khedr M; Norman BP; Bou-Gharios G; Gallagher JA; Gornall M; Jackson R; Imrich R; Rovensky J; Rudebeck M; Olsson B
    Mol Genet Metab Rep; 2022 Mar; 30():100846. PubMed ID: 35242577
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Frequency, diagnosis, pathogenesis and management of osteoporosis in alkaptonuria: data analysis from the UK National Alkaptonuria Centre.
    Ranganath LR; Khedr M; Vinjamuri S; Gallagher JA
    Osteoporos Int; 2021 May; 32(5):927-938. PubMed ID: 33118050
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preventive use of nitisinone in alkaptonuria.
    Wolffenbuttel BHR; Heiner-Fokkema MR; van Spronsen FJ
    Orphanet J Rare Dis; 2021 Aug; 16(1):343. PubMed ID: 34344451
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Urine homogentisic acid and tyrosine: simultaneous analysis by liquid chromatography tandem mass spectrometry.
    Hughes AT; Milan AM; Christensen P; Ross G; Davison AS; Gallagher JA; Dutton JJ; Ranganath LR
    J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Jul; 963():106-12. PubMed ID: 24952314
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nitisinone causes acquired tyrosinosis in alkaptonuria.
    Khedr M; Cooper MS; Hughes AT; Milan AM; Davison AS; Norman BP; Sutherland H; Jarvis JC; Fitzgerald R; Markinson L; Psarelli EE; Ghane P; Deutz NEP; Gallagher JA; Ranganath LR
    J Inherit Metab Dis; 2020 Sep; 43(5):1014-1023. PubMed ID: 32083330
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Data on items of AKUSSI in Alkaptonuria collected over three years from the United Kingdom National Alkaptonuria Centre and the impact of nitisinone.
    Griffin R; Psarelli EE; Cox TF; Khedr M; Milan AM; Davison AS; Hughes AT; Usher JL; Taylor S; Loftus N; Daroszewska A; West E; Jones A; Briggs M; Fisher M; McCormick M; Judd S; Vinjamuri S; Sireau N; Dillon JP; Devine JM; Hughes G; Harrold J; Barton GJ; Jarvis JC; Gallagher JA; Ranganath LR
    Data Brief; 2018 Oct; 20():1620-1628. PubMed ID: 30263914
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alkaptonuria: Current Perspectives.
    Zatkova A; Ranganath L; Kadasi L
    Appl Clin Genet; 2020; 13():37-47. PubMed ID: 32158253
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Determinants of tyrosinaemia during nitisinone therapy in alkaptonuria.
    Ranganath LR; Milan AM; Hughes AT; Davison AS; M K; Norman BP; Bou-Gharios G; Gallagher JA; Imrich R; Arnoux JB; Rudebeck M; Olsson B
    Sci Rep; 2022 Sep; 12(1):16083. PubMed ID: 36167967
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increased prevalence of Parkinson's disease in alkaptonuria.
    Ranganath L; Khedr M; Milan AM; Davison AS; Norman BP; Janssen MCH; Lock E; Bou-Gharios G; Gallagher JA
    JIMD Rep; 2023 Jul; 64(4):282-292. PubMed ID: 37404676
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analysis of Melanin-like Pigment Synthesized from Homogentisic Acid, with or without Tyrosine, and Its Implications in Alkaptonuria.
    Taylor AM; Vercruysse KP
    JIMD Rep; 2017; 35():79-85. PubMed ID: 27943071
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of para-Hydroxyphenylpyruvate Dioxygenase by Analogues of the Herbicide Nitisinone As a Strategy to Decrease Homogentisic Acid Levels, the Causative Agent of Alkaptonuria.
    Laschi M; Bernardini G; Dreassi E; Millucci L; Geminiani M; Braconi D; Marzocchi B; Botta M; Manetti F; Santucci A
    ChemMedChem; 2016 Apr; 11(7):674-8. PubMed ID: 26947423
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alkaptonuria - Past, present and future.
    Davison AS; Norman BP
    Adv Clin Chem; 2023; 114():47-81. PubMed ID: 37268334
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.